Mark J. Gergen, Senior VP, Corporate Development at AMYLIN PHARMACEUTICALS INC (AMLN), sold 500 shares at $37.75 ($19K) on 2007-03-01, disclosed to the SEC on 2007-03-02.
Scheduled sale ($19k) by Senior VP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| MRTX | SELL | 2016-01-19 | $518K | — | Filing → |
| AMLN | SELL | 2012-03-02 | $32K | — | Filing → |
| AMLN | SELL | 2012-02-24 | $128K | — | Filing → |